Evotec and Lilly enter into collaboration

Cooperation launched to research drug discovery in the field of metabolic diseases

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company (“Lilly”) in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention.

The partners are leveraging Evotec's patient database on kidney disease to identify and validate promising novel targets for new therapeutic approaches. (Image: ©Sergey Nivens/stock.adobe.com)

Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation.

The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are excited to enter into this research partnership with Lilly. Over a period of several years, Evotec has systematically built a proprietary patient database by conducting multi-omics analyses of biospecimens from patient biobanks covering metabolic and kidney diseases. Evotec’s patient-derived molecular data in combination with our omics-supported multimodality drug discovery platform delivers highest quality drug candidates for our partners. We are proud to collaborate with Lilly in diabetes and kidney diseases as they are one of the leading companies in these areas.”

More News

To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)
To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)

"Stealth Effect"

An experiment led by a team of DESY and Universität Hamburg scientists has discovered that gold nanoparticles can move through liquid ...

Read more …
Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)

Cooperation for faster drug discovery

The mutual project “LigandML” receives funding by the IFB Hamburg aiming to leverage experimental capabilities for better data quality paired ...

Read more …